Mochida Pharmaceutical Co., Ltd. (4534.T)
JPY 2953.0
(-0.07%)
JPY 2953.0
(-0.07%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 5.8 Billion JPY | -31.79% |
| 2022 | 8.5 Billion JPY | -40.89% |
| 2021 | 14.39 Billion JPY | 19.9% |
| 2020 | 12 Billion JPY | 36.29% |
| 2019 | 8.8 Billion JPY | -16.84% |
| 2018 | 10.59 Billion JPY | -9.19% |
| 2017 | 11.66 Billion JPY | 2.53% |
| 2016 | 11.37 Billion JPY | -6.42% |
| 2015 | 12.15 Billion JPY | 3.98% |
| 2014 | 11.68 Billion JPY | -29.58% |
| 2013 | 16.6 Billion JPY | 18.43% |
| 2012 | 14.01 Billion JPY | -6.11% |
| 2011 | 14.92 Billion JPY | 29.7% |
| 2010 | 11.51 Billion JPY | -17.49% |
| 2009 | 13.94 Billion JPY | 7.43% |
| 2008 | 12.98 Billion JPY | 9.8% |
| 2007 | 11.82 Billion JPY | 13.75% |
| 2006 | 10.39 Billion JPY | 18.16% |
| 2005 | 8.79 Billion JPY | 84.52% |
| 2004 | 4.76 Billion JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 2.19 Billion JPY | 19809.09% |
| 2024 Q2 | 1.6 Billion JPY | -26.8% |
| 2023 FY | 5.8 Billion JPY | -31.79% |
| 2023 Q4 | 11 Million JPY | -99.4% |
| 2023 Q3 | 1.83 Billion JPY | 27.97% |
| 2023 Q1 | 2.51 Billion JPY | 236.02% |
| 2023 Q2 | 1.43 Billion JPY | -42.86% |
| 2022 Q1 | 4.26 Billion JPY | 216.63% |
| 2022 Q4 | -1.84 Billion JPY | -136.42% |
| 2022 Q3 | 5.07 Billion JPY | 400.69% |
| 2022 Q2 | 1.01 Billion JPY | -76.23% |
| 2022 FY | 8.5 Billion JPY | -40.89% |
| 2021 Q4 | 1.34 Billion JPY | -80.52% |
| 2021 Q1 | 3.18 Billion JPY | 288.64% |
| 2021 FY | 14.39 Billion JPY | 19.9% |
| 2021 Q2 | 2.94 Billion JPY | -7.38% |
| 2021 Q3 | 6.91 Billion JPY | 134.53% |
| 2020 Q2 | 2.63 Billion JPY | -42.64% |
| 2020 FY | 12 Billion JPY | 36.29% |
| 2020 Q1 | 4.59 Billion JPY | 911.89% |
| 2020 Q4 | 819 Million JPY | -79.29% |
| 2020 Q3 | 3.95 Billion JPY | 50.09% |
| 2019 Q2 | 1.68 Billion JPY | -62.8% |
| 2019 Q1 | 4.51 Billion JPY | 749.28% |
| 2019 FY | 8.8 Billion JPY | -16.84% |
| 2019 Q4 | 454 Million JPY | -78.91% |
| 2019 Q3 | 2.15 Billion JPY | 28.08% |
| 2018 FY | 10.59 Billion JPY | -9.19% |
| 2018 Q2 | 1.45 Billion JPY | -76.41% |
| 2018 Q3 | 3.66 Billion JPY | 151.82% |
| 2018 Q4 | -696 Million JPY | -119.0% |
| 2018 Q1 | 6.16 Billion JPY | 1227.42% |
| 2017 Q4 | -547 Million JPY | -113.28% |
| 2017 Q3 | 4.12 Billion JPY | 92.97% |
| 2017 Q1 | 5.95 Billion JPY | 447.37% |
| 2017 FY | 11.66 Billion JPY | 2.53% |
| 2017 Q2 | 2.13 Billion JPY | -64.14% |
| 2016 Q2 | 3.11 Billion JPY | -24.34% |
| 2016 Q4 | -1.71 Billion JPY | -129.27% |
| 2016 Q3 | 5.85 Billion JPY | 87.99% |
| 2016 FY | 11.37 Billion JPY | -6.42% |
| 2016 Q1 | 4.11 Billion JPY | 2266.09% |
| 2015 FY | 12.15 Billion JPY | 3.98% |
| 2015 Q4 | 174 Million JPY | -96.46% |
| 2015 Q3 | 4.91 Billion JPY | 79.13% |
| 2015 Q2 | 2.74 Billion JPY | -36.36% |
| 2015 Q1 | 4.31 Billion JPY | 62.95% |
| 2014 Q2 | 1.81 Billion JPY | -26.42% |
| 2014 Q3 | 4.77 Billion JPY | 163.59% |
| 2014 Q4 | 2.64 Billion JPY | -44.5% |
| 2014 FY | 11.68 Billion JPY | -29.58% |
| 2014 Q1 | 2.46 Billion JPY | -10.77% |
| 2013 Q1 | 4.1 Billion JPY | 67.77% |
| 2013 Q3 | 5.9 Billion JPY | 54.2% |
| 2013 Q4 | 2.75 Billion JPY | -53.32% |
| 2013 FY | 16.6 Billion JPY | 18.43% |
| 2013 Q2 | 3.83 Billion JPY | -6.74% |
| 2012 FY | 14.01 Billion JPY | -6.11% |
| 2012 Q3 | 3.56 Billion JPY | -12.8% |
| 2012 Q4 | 2.44 Billion JPY | -31.29% |
| 2012 Q1 | 3.92 Billion JPY | 185.71% |
| 2012 Q2 | 4.08 Billion JPY | 4.23% |
| 2011 Q1 | 1.1 Billion JPY | 126.18% |
| 2011 Q2 | 6.26 Billion JPY | 466.46% |
| 2011 Q4 | 1.37 Billion JPY | -77.82% |
| 2011 FY | 14.92 Billion JPY | 29.7% |
| 2011 Q3 | 6.18 Billion JPY | -1.26% |
| 2010 Q2 | 3.15 Billion JPY | -10.1% |
| 2010 Q1 | 3.5 Billion JPY | 152.16% |
| 2010 Q3 | 4.36 Billion JPY | 38.53% |
| 2010 Q4 | 489 Million JPY | -88.8% |
| 2010 FY | 11.51 Billion JPY | -17.49% |
| 2009 Q2 | 4.12 Billion JPY | 3.59% |
| 2009 Q4 | 1.39 Billion JPY | -68.76% |
| 2009 Q3 | 4.44 Billion JPY | 7.83% |
| 2009 Q1 | 3.98 Billion JPY | 152.73% |
| 2009 FY | 13.94 Billion JPY | 7.43% |
| 2008 Q4 | 1.57 Billion JPY | -67.21% |
| 2008 Q2 | 3.25 Billion JPY | 0.0% |
| 2008 FY | 12.98 Billion JPY | 9.8% |
| 2008 Q3 | 4.8 Billion JPY | 47.64% |
| 2007 FY | 11.82 Billion JPY | 13.75% |
| 2006 FY | 10.39 Billion JPY | 18.16% |
| 2005 FY | 8.79 Billion JPY | 84.52% |
| 2004 FY | 4.76 Billion JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 5.11 Billion JPY | -13.495% |
| Takeda Pharmaceutical Company Limited | 214.07 Billion JPY | 97.289% |
| Sumitomo Pharma Co., Ltd. | -354.19 Billion JPY | 101.638% |
| Shionogi & Co., Ltd. | 171.46 Billion JPY | 96.616% |
| Wakamoto Pharmaceutical Co.,Ltd. | -195.51 Million JPY | 3068.119% |
| Nippon Shinyaku Co., Ltd. | 31.38 Billion JPY | 81.511% |
| Kaken Pharmaceutical Co., Ltd. | 9.51 Billion JPY | 38.999% |
| Eisai Co., Ltd. | 53.4 Billion JPY | 89.135% |
| Morishita Jintan Co., Ltd. | 716 Million JPY | -710.475% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.16 Billion JPY | 55.928% |
| Fuso Pharmaceutical Industries,Ltd. | 1.96 Billion JPY | -195.468% |
| Nippon Chemiphar Co., Ltd. | -494 Million JPY | 1274.696% |
| Tsumura & Co. | 20.01 Billion JPY | 71.011% |
| Kissei Pharmaceutical Co., Ltd. | 4.01 Billion JPY | -44.461% |
| Torii Pharmaceutical Co., Ltd. | 5.03 Billion JPY | -15.23% |
| Towa Pharmaceutical Co., Ltd. | 17.64 Billion JPY | 67.118% |
| Fuji Pharma Co., Ltd. | 3.85 Billion JPY | -50.415% |
| Zeria Pharmaceutical Co., Ltd. | 9.71 Billion JPY | 40.278% |
| KYORIN Holdings, Inc. | 6.01 Billion JPY | 3.492% |
| Taiko Pharmaceutical Co.,Ltd. | -3.07 Billion JPY | 288.47% |
| Daito Pharmaceutical Co.,Ltd. | 3.89 Billion JPY | -49.024% |
| SymBio Pharmaceuticals Limited | -811.66 Million JPY | 814.947% |
| MedRx Co., Ltd | -933 Million JPY | 721.972% |
| Mizuho Medy Co.,Ltd. | 5.15 Billion JPY | -12.636% |
| Solasia Pharma K.K. | -1.13 Billion JPY | 609.482% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 344.852% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 6.5 Billion JPY | 10.723% |
| Sawai Group Holdings Co., Ltd. | 18.88 Billion JPY | 69.274% |
| Cyfuse Biomedical K.K. | -697.43 Million JPY | 932.046% |
| Toho Holdings Co., Ltd. | 19.33 Billion JPY | 69.981% |
| Koa Shoji Holdings Co.,Ltd. | 4.38 Billion JPY | -32.419% |